PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma

Taispeáin leaganacha eile (1)

Background: PIM serine/threonine kinases are often highly expressed in haematological malignancies. We have shown that PIM inhibitors reduced the survival and migration of leukaemic cells. Here, we investigated PIM kinases in diffuse large B-cell lymphoma (DLBCL) biopsy samples and DLBCL cell lines....

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Brault, L, Menter, T, Obermann, E, Knapp, S, Thommen, S, Schwaller, J, Tzankov, A
Formáid:	Journal article
Foilsithe / Cruthaithe:	2012

Míreanna comhchosúla

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
de réir: Brault, L, et al.
Foilsithe / Cruthaithe: (2012)

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
de réir: Brault, L, et al.
Foilsithe / Cruthaithe: (2010)

STUDYING THE ROLE OF PIM KINASES IN FLT3-ITD-INDUCED LEUKEMIA REVEALED PIM1 AS REGULATOR OF CXCL12/CXCR4-MEDIATED HOMING AND MIGRATION
de réir: Brault, L, et al.
Foilsithe / Cruthaithe: (2009)

Dissecting Proto-Oncogenic PIM Serine/Threonine Kinases in FLT3-ITD-Induced Leukemogenesis: PIM1 Regulates CXCL12/CXCR4-Mediated Homing and Migration
de réir: Gasser, C, et al.
Foilsithe / Cruthaithe: (2008)

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
de réir: Grundler, R, et al.
Foilsithe / Cruthaithe: (2009)

Structure and substrate specificity of the Pim-1 kinase
de réir: Bullock, A, et al.
Foilsithe / Cruthaithe: (2005)

Structure and substrate specificity of the Pim-1 kinase.
de réir: Bullock, A, et al.
Foilsithe / Cruthaithe: (2005)

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
de réir: Pogacic, V, et al.
Foilsithe / Cruthaithe: (2007)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
de réir: Bullock, A, et al.
Foilsithe / Cruthaithe: (2009)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
de réir: Akué-Gédu, R, et al.
Foilsithe / Cruthaithe: (2009)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1
de réir: Debreczeni, J, et al.
Foilsithe / Cruthaithe: (2006)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1.
de réir: Debreczeni, J, et al.
Foilsithe / Cruthaithe: (2006)

Electrostatically Enhanced Association of a Pim Kinase Substrate Revealed by Stochastic Detection
de réir: Harrington, L, et al.
Foilsithe / Cruthaithe: (2014)

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
de réir: Bataille, C, et al.
Foilsithe / Cruthaithe: (2017)

Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
de réir: Ekambaram, R, et al.
Foilsithe / Cruthaithe: (2013)

Stochastic detection of Pim protein kinases reveals electrostatically enhanced association of a peptide substrate.
de réir: Harrington, L, et al.
Foilsithe / Cruthaithe: (2013)

T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
de réir: Herbert, K, et al.
Foilsithe / Cruthaithe: (2018)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
de réir: López-Ramos, M, et al.
Foilsithe / Cruthaithe: (2010)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
de réir: López-Ramos, M, et al.
Foilsithe / Cruthaithe: (2010)

Effect of single amino acid substitution observed in cancer on Pim-1 kinase thermodynamic stability and structure
de réir: Lori, C, et al.
Foilsithe / Cruthaithe: (2013)

Crystal structure-guided design of bisubstrate inhibitors and photoluminiscent probes for protein kinases of the PIM family
de réir: Nonga, OE, et al.
Foilsithe / Cruthaithe: (2021)

Bromodomains as therapeutic targets.
de réir: Muller, S, et al.
Foilsithe / Cruthaithe: (2011)

Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma.
de réir: Knapp, S
Foilsithe / Cruthaithe: (2013)

Targeting kinases for the treatment of inflammatory diseases.
de réir: Müller, S, et al.
Foilsithe / Cruthaithe: (2010)

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents
de réir: Da Costa, D, et al.
Foilsithe / Cruthaithe: (2010)

INTRACELLULAR MARKERS OF DIFFERENTIATION IN BURKITTS-LYMPHOMA
de réir: Gallagher, C, et al.
Foilsithe / Cruthaithe: (1984)

Therapeutic interventions for Burkitt lymphoma in children.
de réir: Okebe, J, et al.
Foilsithe / Cruthaithe: (2011)

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblas tic Leukaemia (ALL) Cells to DNA Damaging Agents
de réir: Da Costa, D, et al.
Foilsithe / Cruthaithe: (2010)

Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
de réir: Bullock, A, et al.
Foilsithe / Cruthaithe: (2005)

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
de réir: Miduturu, C, et al.
Foilsithe / Cruthaithe: (2011)

Identification of molecular factors mediating therapeutic resistance in diffuse large B-cell lymphoma (DLBCL)
de réir: Peng, Chenchen
Foilsithe / Cruthaithe: (2024)

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
de réir: Camilleri, E, et al.
Foilsithe / Cruthaithe: (2012)

Novel therapeutic approach for cutaneous T-Cell lymphoma
de réir: Low, Jian Hui
Foilsithe / Cruthaithe: (2016)

Recently targeted kinases and their inhibitors-the path to clinical trials.
de réir: Knapp, S, et al.
Foilsithe / Cruthaithe: (2014)

Recently targeted kinases and their inhibitors - the path to clinical trials
de réir: Knapp, S, et al.
Foilsithe / Cruthaithe: (2014)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights (September, pg 3175, 2010)
de réir: Lopez-Ramos, M, et al.
Foilsithe / Cruthaithe: (2011)

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
de réir: Kizhakeyil, A, et al.
Foilsithe / Cruthaithe: (2021)

Emerging intrinsic therapeutic targets for metastatic breast cancer
de réir: Li, Jiawei, et al.
Foilsithe / Cruthaithe: (2023)

Diffuse large B-cell lymphoma
de réir: Gatter, K, et al.
Foilsithe / Cruthaithe: (2010)

Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
de réir: Li, Audrey
Foilsithe / Cruthaithe: (2024)